Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans

Journal of Lipid Research

Volumn 57, Issue 12, 2016, Pages 2130-2137

  Takahashi, Shogo ^a   Fukami, Tatsuki ^a   Masuo, Yusuke ^a   Brocker, Chad N ^a   Xie, Cen ^a   Krausz, Kristopher W ^a   Wolf, C Roland ^b   Henderson, Colin J ^b   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Chenodeoxycholic acid; Cyp2c70; Cytochrome p450; Enzyme kinetics; Liver; Muricholic acid; Ursodeoxycholic acid

Indexed keywords

ALPHA MURICHOLIC ACID; BETA MURICHOLIC ACID; CHENODEOXYCHOLIC ACID; CYTOCHROME P450; CYTOCHROME P450 2C70; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; CHOLIC ACID DERIVATIVE; CYTOCHROME P-450 2C70, MOUSE; MURICHOLIC ACID;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BILE ACID METABOLISM; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; LIPOGENESIS; LIVER METABOLISM; MALE; METABOLOMICS; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECIES DIFFERENCE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; COMPARATIVE STUDY; ENZYMOLOGY; GENE EXPRESSION; HEP-G2 CELL LINE; KINETICS; KNOCKOUT MOUSE; LIVER; OXIDATION REDUCTION REACTION; PHYSIOLOGY;

ANIMALS; CHOLIC ACIDS; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION; HEP G2 CELLS; HUMANS; KINETICS; LIVER; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATION-REDUCTION; SPECIES SPECIFICITY;

EID: 85002556764     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M071183     Document Type: Article

References (37)

1. Russell, D. W. 2003. The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72:137-174.
2. Hofmann, A. F. 2009. The enterohepatic circulation of bile acids in mammals: form and functions. Front. Biosci. (Landmark Ed.). 14:2584-2598.
3. Matsubara, T., F. Li, and F. J. Gonzalez. 2013. FXR signaling in the enterohepatic system. Mol. Cell. Endocrinol. 368:17-29.
4. Gonzalez, F. J. 2012. Nuclear receptor control of enterohepatic circulation. Compr. Physiol. 2:2811-2828.
5. Deo, A. K., and S. M. Bandiera. 2008. Identification of human hepatic cytochrome p450 enzymes involved in the biotransformation of cholic and chenodeoxycholic acid. Drug Metab. Dispos. 36:1983-1991.
6. Hardison, W. G. 1978. Hepatic taurine concentration and dietary taurine as regulators of bile acid conjugation with taurine. Gastroenterology. 75:71-75.
7. Jiang, C., C. Xie, F. Li, L. Zhang, R. G. Nichols, K. W. Krausz, J. Cai, Y. Qi, Z. Z. Fang, S. Takahashi, et al. 2015. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Invest. 125:386-402.
8. Jiang, C., C. Xie, Y. Lv, J. Li, K. W. Krausz, J. Shi, C. N. Brocker, D. Desai, S. G. Amin, W. H. Bisson, et al. 2015. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun. 6:10166.
9. Li, F., C. Jiang, K. W. Krausz, Y. Li, I. Albert, H. Hao, K. M. Fabre, J. B. Mitchell, A. D. Patterson, and F. J. Gonzalez. 2013. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat. Commun. 4:2384.
10. Russell, D. W., and K. D. Setchell. 1992. Bile acid biosynthesis. Biochemistry. 31:4737-4749.
11. Inagaki, T., M. Choi, A. Moschetta, L. Peng, C. L. Cummins, J. G. McDonald, G. Luo, S. A. Jones, B. Goodwin, J. A. Richardson, et al. 2005. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2:217-225.
12. Nelson, D. R., D. C. Zeldin, S. M. Hoffman, L. J. Maltais, H. M. Wain, and D. W. Nebert. 2004. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternativesplice variants. Pharmacogenetics. 14:1-18.
13. Scheer, N., L. A. McLaughlin, A. Rode, A. K. Macleod, C. J. Henderson, and C. R. Wolf. 2014. Deletion of 30 murine cytochrome p450 genes results in viable mice with compromised drug metabolism. Drug Metab. Dispos. 42:1022-1030.
14. Cheung, C., and F. J. Gonzalez. 2008. Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J. Pharmacol. Exp. Ther. 327:288-299.
15. Scheer, N., and C. R. Wolf. 2014. Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications. Xenobiotica. 44:96-108.
16. van Herwaarden, A. E., E. Wagenaar, C. M. van der Kruijssen, R. A. van Waterschoot, J. W. Smit, J. Y. Song, M. A. van der Valk, O. van Tellingen, J. W. van der Hoorn, H. Rosing, et al. 2007. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J. Clin. Invest. 117:3583-3592.
17. Hasegawa, M., Y. Kapelyukh, H. Tahara, J. Seibler, A. Rode, S. Krueger, D. N. Lee, C. R. Wolf, and N. Scheer. 2011. Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line. Mol. Pharmacol. 80:518-528.
18. Scheer, N., Y. Kapelyukh, J. McEwan, V. Beuger, L. A. Stanley, A. Rode, and C. R. Wolf. 2012. Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines. Mol. Pharmacol. 81:63-72.
19. Dragin, N., S. Uno, B. Wang, T. P. Dalton, and D. W. Nebert. 2007. Generation of 'humanized' hCYP1A1-1A2-Cyp1a1/1a2 (-/-) mouse line. Biochem. Biophys. Res. Commun. 359:635-642.
20. Scheer, N., Y. Kapelyukh, L. Chatham, A. Rode, S. Buechel, and C. R. Wolf. 2012. Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines. Mol. Pharmacol. 82:1022-1029.
21. Tanaka, N., S. Takahashi, Y. Zhang, K. W. Krausz, P. B. Smith, A. D. Patterson, and F. J. Gonzalez. 2015. Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and cholinedeficient diet. Biochim. Biophys. Acta. 1852:1242-1252.
22. Gu, J., Y. Weng, Q. Y. Zhang, H. Cui, M. Behr, L. Wu, W. Yang, L. Zhang, and X. Ding. 2003. Liver-specific deletion of the NADPHcytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J. Biol. Chem. 278:25895-25901.
23. Cheng, X., Y. Zhang, and C. D. Klaassen. 2014. Decreased bile-acid synthesis in livers of hepatocyte-conditional NADPH-cytochrome P450 reductase-null mice results in increased bile acids in serum. J. Pharmacol. Exp. Ther. 351:105-113.
24. Fedorowski, T., G. Salen, G. S. Tint, and E. Mosbach. 1979. Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria. Gastroenterology. 77:1068-1073.
25. Hofmann, A. F. 2004. Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab. Rev. 36:703-722.
26. Sayin, S. I., A. Wahlstrom, J. Felin, S. Jantti, H. U. Marschall, K. Bamberg, B. Angelin, T. Hyotylainen, M. Oresic, and F. Backhed. 2013. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17:225-235.
27. Mueller, M., A. Thorell, T. Claudel, P. Jha, H. Koefeler, C. Lackner, B. Hoesel, G. Fauler, T. Stojakovic, C. Einarsson, et al. 2015. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J. Hepatol. 62:1398-1404.
28. Katagiri, K., T. Nakai, M. Hoshino, T. Hayakawa, H. Ohnishi, Y. Okayama, T. Yamada, T. Ohiwa, M. Miyaji, and T. Takeuchi. 1992. Tauro-beta-muricholate preserves choleresis and prevents taurocholate-induced cholestasis in colchicine-treated rat liver. Gastroenterology. 102:1660-1667.
29. Löfgren, S., R. M. Baldwin, M. Carlerös, Y. Terelius, R. Fransson-Steen, J. Mwinyi, D. J. Waxman, and M. Ingelman-Sundberg. 2009. Regulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormone. Drug Metab. Dispos. 37:1505-1512.
30. Greathouse, K. L., C. C. Harris, and S. J. Bultman. 2015. Dysfunctional families: Clostridium scindens and secondary bile acids inhibit the growth of Clostridium difficile. Cell Metab. 21:9-10.
31. Buffie, C. G., V. Bucci, R. R. Stein, P. T. McKenney, L. Ling, A. Gobourne, D. No, H. Liu, M. Kinnebrew, A. Viale, et al. 2015. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 517:205-208.
32. Hirano, S., and N. Masuda. 1981. Epimerization of the 7-hydroxy group of bile acids by the combination of two kinds of microorganisms with 7 alpha- and 7 beta-hydroxysteroid dehydrogenase activity, respectively. J. Lipid Res. 22:1060-1068.
33. de Aguiar Vallim, T. Q., E. J. Tarling, H. Ahn, L. R. Hagey, C. E. Romanoski, R. G. Lee, M. J. Graham, H. Motohashi, M. Yamamoto, and P. A. Edwards. 2015. MAFG is a transcriptional repressor of bile acid synthesis and metabolism. Cell Metab. 21:298-310.
34. Seeley, R. J., A. P. Chambers, and D. A. Sandoval. 2015. The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes. Cell Metab. 21:369-378.
35. Jones, R. D., A. M. Lopez, E. Y. Tong, K. S. Posey, J. C. Chuang, J. J. Repa, and S. D. Turley. 2015. Impact of physiological levels of chenodeoxycholic acid supplementation on intestinal and hepatic bile acid and cholesterol metabolism in Cyp7a1-deficient mice. Steroids. 93:87-95.
36. Thomas, C., A. Gioiello, L. Noriega, A. Strehle, J. Oury, G. Rizzo, A. Macchiarulo, H. Yamamoto, C. Mataki, M. Pruzanski, et al. 2009. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10:167-177.
37. Botham, K. M., and G. S. Boyd. 1983. The metabolism of chenodeoxycholic acid to beta-muricholic acid in rat liver. Eur. J. Biochem. 134:191-196.